Trade BioCryst - BCRX CFD
Add to favourite- Summary
- Historical Data
| Spread | 0.07 | ||||||||
|
Long position overnight fee
Long position overnight funding adjustment
Go to platform | -0.023512% | ||||||||
|
Short position overnight fee
Short position overnight funding adjustment
Go to platform | 0.00129% | ||||||||
| Overnight fee time | 22:00 (UTC) | ||||||||
| Min traded quantity | 1 | ||||||||
| Currency | USD | ||||||||
| Margin | 5.00% | ||||||||
| Stock exchange | United States of America | ||||||||
| Commission on trade | 0% |
| Prev. Close | 9.34 |
| Open | 9.39 |
| 1-Year Change | 62.18% |
| Day's Range | 9.13 - 9.39 |
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
| Date | Close | Change | Change (%) | Open | High | Low |
|---|---|---|---|---|---|---|
| Feb 21, 2025 | 9.17 | -0.22 | -2.34% | 9.39 | 9.41 | 9.12 |
| Feb 20, 2025 | 9.34 | -0.03 | -0.32% | 9.37 | 9.46 | 9.27 |
| Feb 19, 2025 | 9.35 | 0.04 | 0.43% | 9.31 | 9.44 | 9.28 |
| Feb 18, 2025 | 9.32 | 0.24 | 2.64% | 9.08 | 9.42 | 9.06 |
| Feb 14, 2025 | 9.01 | 0.22 | 2.50% | 8.79 | 9.07 | 8.70 |
| Feb 13, 2025 | 8.78 | 0.05 | 0.57% | 8.73 | 8.86 | 8.59 |
| Feb 12, 2025 | 8.75 | -0.13 | -1.46% | 8.88 | 8.96 | 8.69 |
| Feb 11, 2025 | 8.95 | 0.42 | 4.92% | 8.53 | 8.96 | 8.51 |
| Feb 10, 2025 | 8.59 | -0.09 | -1.04% | 8.68 | 8.77 | 8.50 |
| Feb 7, 2025 | 8.70 | 0.00 | 0.00% | 8.70 | 8.84 | 8.56 |
| Feb 6, 2025 | 8.69 | 0.09 | 1.05% | 8.60 | 8.83 | 8.45 |
| Feb 5, 2025 | 8.57 | 0.40 | 4.90% | 8.17 | 8.96 | 8.17 |
| Feb 4, 2025 | 8.05 | 0.51 | 6.76% | 7.54 | 8.09 | 7.54 |
| Feb 3, 2025 | 7.59 | -0.05 | -0.65% | 7.64 | 7.68 | 7.51 |
| Jan 31, 2025 | 7.86 | 0.06 | 0.77% | 7.80 | 7.99 | 7.78 |
| Jan 30, 2025 | 7.83 | -0.18 | -2.25% | 8.01 | 8.11 | 7.77 |
| Jan 29, 2025 | 7.99 | 0.13 | 1.65% | 7.86 | 8.06 | 7.82 |
| Jan 28, 2025 | 7.89 | -0.09 | -1.13% | 7.98 | 8.03 | 7.87 |
| Jan 27, 2025 | 7.97 | 0.44 | 5.84% | 7.53 | 8.05 | 7.50 |
| Jan 24, 2025 | 7.60 | 0.01 | 0.13% | 7.59 | 7.81 | 7.51 |
Trading calculator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
- 1:1
- 2:1
- 3:1
- 5:1
- 10:1
- 20:1
- 20
- 100
- 500
- 1000
- 10000
BioCryst Company profile
BioCryst (BCRX) is a commercial-stage biotech firm that discovers novel, oral, small-molecule medicines.
The company focuses on oral treatments for rare diseases in which significant unmet medical needs exist. BioCryst’s drug portfolio consists of ORLADEYO for prevention of hereditary angioedema. ORLADEYO has been approved in the US, EU, UK, Japan and UAE. Other drugs like RAPIACTA, RAPIVAB and PERAMIFLU are approved in select geographies.
The company is developing an oral small molecule Factor D inhibitor to treat patients with paroxysmal nocturnal hemoglobinuria and other complement-mediated diseases.
According to the company, its focus on rare diseases market helps it control costs effectively. BioCryst selects disease targets and product candidates in which a small molecule would offer a significant benefit over existing products or would be the first to market.
BioCryst’s US headquarters is located in Durham, North Carolina while its European headquarters is in Dublin, Ireland. Jon P Stonehouse is the chief executive officer and William P Sheridan is the chief medical officer of BioCryst.
The company was founded in 1966. It completed its initial public offering (IPO) in March 1994 and is listed on the Nasdaq stock exchange under the ticker symbol BCRX. According to the company’s price history, BCRX stock price hit an all-time high of $37.25 on 1 March 2000.
You can follow the ups and downs of the BioCryst stock price at Capital.com. Always stay on top of the latest price developments with our live BCRX stock chart.
| Industry: | Bio Therapeutic Drugs |
4505 Emperor Blvd Ste 200
DURHAM
NORTH CAROLINA 27703-8457
US
News
Microsoft Stock Price Forecast for 2025 and beyond: Third party price target
We assess the likely level of the Microsoft stock price in 5 years, and possible drivers behind the stock’s past performance. Read on...
18:29, 7 February 2025
Ripple XRP price prediction: Third-party price target
Discover the ripple (XRP) price predictions for 2025 and beyond, with analyst price targets and CFDs trading strategies on Capital.com
15:29, 6 February 2025
Apple (AAPL) stock price forecast: third-party price target
We looked at the forecasts for Apple stock in 10 years to see where the price would likely be at that point and the challenges the company could face. Read more.
11:22, 6 February 2025
FARTCOIN price prediction: Third-party price target
Read our FARTCOIN price prediction for 2025 and beyond, with insights from third-party analysts and market experts
10:18, 29 January 2025
MELANIA coin ($MELANIA) price prediction: Third party price target
Read our MELANIA crypto price prediction for 2025 and beyond, with insights from third-party analysts and market experts.
11:33, 22 January 2025
TRUMP coin ($TRUMP) price prediction: third-party price target
Read our TRUMP crypto price prediction for 2025 and beyond, with insights from third-party analysts and market experts
10:52, 22 January 2025
Ethereum price prediction: Third party data round up
What is the outlook for ETH as a long-term investment?
16:37, 7 January 2025People also watch
Still looking for a broker you can trust?
Join the 690,000+ traders worldwide that chose to trade with Capital.com